Quantitative proteomics analysis of early recurrence/metastasis of huge hepatocellular carcinoma following radical resection

Proteome Science

Volumn 12, Issue 1, 2014, Pages

  Huang, Xinhui ^a   Zeng, Yongyi ^a   Xing, Xiaohua ^a   Zeng, Jinhua ^a   Gao, Yunzhen ^a   Cai, Zhixiong ^a   Xu, Bo ^a   Liu, Xiaolong ^a   Huang, Aimin ^a   Liu, Jingfeng ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Early recurrence metastasis; Huge hepatocellular carcinoma (H HCC); iTRAQ; Potential prognostic biomarker; Quantitative proteomics

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; APOLIPOPROTEIN A2; BILIVERDIN; BILIVERDIN REDUCTASE A; GALECTIN 4; INITIATION FACTOR 3; LACTOFERRIN; MESSENGER RNA; OXIDOREDUCTASE; PROTEIN; PROTEIN S 100; RIBONUCLEOPROTEIN; S100A12 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RECURRENCE; HUMAN; LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; LIVER RESECTION; METASTASIS; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PROTEIN EXPRESSION; PROTEOMICS; QUANTITATIVE ANALYSIS; RADICAL RESECTION; REGULATORY MECHANISM; TANDEM MASS SPECTROMETRY; UPREGULATION;

EID: 84900831927     PISSN: None     EISSN: 14775956     Source Type: Journal    
DOI: 10.1186/1477-5956-12-22     Document Type: Article

References (69)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
2. Chen WQ, Zeng HM, Zheng RS, Zhang SW, He J. Cancer incidence and mortality in china, 2007. Chin J Cancer Res 2012, 24:1-8. 10.1007/s11670-012-0001-6, 3555260, 23359628.
3. Chen XP, Qiu FZ, Wu ZD, Zhang BX. Hepatectomy for huge hepatocellular carcinoma in 634 cases. World J Gastroenterol 2006, 12:4652-4655.
4. Liau KH, Ruo L, Shia J, Padela A, Gonen M, Jarnagin WR, Fong Y, D'Angelica MI, Blumgart LH, DeMatteo RP. Outcome of partial hepatectomy for large (>10 cm) hepatocellular carcinoma. Cancer 2005, 104:1948-1955. 10.1002/cncr.21415, 16196045.
5. Choi GH, Han DH, Kim DH, Choi SB, Kang CM, Kim KS, Choi JS, Park YN, Park JY, Kim do Y, Han KH, Chon CY, Lee WJ. Outcome after curative resection for a huge (>or = 10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 2009, 198:693-701. 10.1016/j.amjsurg.2008.09.019, 19268907.
6. Ng KM, Yan TD, Black D, Chu FC, Morris DL. Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma. HPB (Oxford) 2009, 11:311-320. 10.1111/j.1477-2574.2009.00044.x, 2727084, 19718358.
7. Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, Grant DR, Greig PD. Prognosis and results after resection of very large (>or = 10 cm) hepatocellular carcinoma. J Gastrointest Surg 2007, 11:589-595. 10.1007/s11605-007-0154-7, 17393258.
8. Lee SG, Hwang S, Jung JP, Lee YJ, Kim KH, Ahn CS. Outcome of patients with huge hepatocellular carcinoma after primary resection and treatment of recurrent lesions. Br J Surg 2007, 94:320-326. 10.1002/bjs.5622, 17205495.
9. Guo K, Kang NX, Li Y, Sun L, Gan L, Cui FJ, Gao MD, Liu KY. Regulation of HSP27 on NF-kappaB pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC Cancer 2009, 9:100. 10.1186/1471-2407-9-100, 2681475, 19331697.
10. Kamiyama T, Takahashi M, Nakanishi K, Yokoo H, Kamachi H, Kobayashi N, Ozaki M, Todo S. alpha-fetoprotein, vascular endothelial growth factor receptor-1 and early recurrence of hepatoma. World J Gastroenterol 2012, 18:340-348. 10.3748/wjg.v18.i4.340, 3261529, 22294840.
11. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S. Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 2005, 103:307-312. 10.1002/cncr.20774, 15593087.
12. Wang SM, Ooi LL, Hui KM. Upregulation of Rac GTPase-activating protein 1 is significantly associated with the early recurrence of human hepatocellular carcinoma. Clin Cancer Res 2011, 17:6040-6051. 10.1158/1078-0432.CCR-11-0557, 21825042.
13. Bozzuto G, Ruggieri P, Molinari A. Molecular aspects of tumor cell migration and invasion. Ann Ist Super Sanita 2010, 46:66-80.
14. Liang S, Xu Z, Xu X, Zhao X, Huang C, Wei Y. Quantitative proteomics for cancer biomarker discovery. Comb Chem High Throughput Screen 2012, 15:221-231. 10.2174/138620712799218635, 22221055.
15. Nikolov M, Schmidt C, Urlaub H. Quantitative mass spectrometry-based proteomics: an overview. Methods Mol Biol 2012, 893:85-100. 10.1007/978-1-61779-885-6_7, 22665296.
16. Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci 2010, 8:70. 10.1186/1477-5956-8-70, 3023778, 21192835.
17. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005, 1:252-262. 10.1038/nchembio736, 16408053.
18. Hudler P, Gorsic M, Komel R. Proteomic strategies and challenges in tumor metastasis research. Clin Exp Metastasis 2010, 27:441-451. 10.1007/s10585-010-9339-7, 20607365.
19. Sun W, Xing B, Sun Y, Du X, Lu M, Hao C, Lu Z, Mi W, Wu S, Wei H, Gao X, Zhu Y, Jiang Y, Qian X, He F. Proteome analysis of hepatocellular carcinoma by two-dimensional difference gel electrophoresis: novel protein markers in hepatocellular carcinoma tissues. Mol Cell Prot 2007, 6:1798-1808.
20. Orimo T, Ojima H, Hiraoka N, Saito S, Kosuge T, Kakisaka T, Yokoo H, Nakanishi K, Kamiyama T, Todo S, Hirohashi S, Kondo T. Proteomic profiling reveals the prognostic value of adenomatous polyposis coli-end-binding protein 1 in hepatocellular carcinoma. Hepatology 2008, 48:1851-1863. 10.1002/hep.22552, 18937283.
21. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 2005, 5:3183-3192. 10.1002/pmic.200401137, 16035113.
22. Gygi SP, Corthals GL, Zhang Y, Rochon Y, Aebersold R. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci U S A 2000, 97:9390-9395. 10.1073/pnas.160270797, 16874, 10920198.
23. Luche S, Santoni V, Rabilloud T. Evaluation of nonionic and zwitterionic detergents as membrane protein solubilizers in two-dimensional electrophoresis. Proteomics 2003, 3:249-253. 10.1002/pmic.200390037, 12627377.
24. Kameshita I, Ishida A, Fujisawa H. Analysis of protein-protein interaction by two-dimensional affinity electrophoresis. Anal Biochem 1998, 262:90-92. 10.1006/abio.1998.2728, 9735155.
25. Ghosh D, Li Z, Tan XF, Lim TK, Mao Y, Lin Q. iTRAQ based quantitative proteomics approach validated the role of calcyclin binding protein (CacyBP) in promoting colorectal cancer metastasis. Mol Cell Prot 2013, 12:1865-1880.
26. Ren F, Wu H, Lei Y, Zhang H, Liu R, Zhao Y, Chen X, Zeng D, Tong A, Chen L, Wei Y, Huang C. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 2010, 9:81. 10.1186/1476-4598-9-81, 2873438, 20403181.
27. Thouvenot E, Urbach S, Vigy O, Seveno M, Galeotti N, Nguyen G, Bockaert J, Marin P. Quantitative proteomic analysis reveals protein expression changes in the murine neuronal secretome during apoptosis. J Proteomics 2012, 77:394-405.
28. Tonack S, Aspinall-O'Dea M, Jenkins RE, Elliot V, Murray S, Lane CS, Kitteringham NR, Neoptolemos JP, Costello E. A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. J Proteomics 2009, 73:352-356. 10.1016/j.jprot.2009.07.009, 19651253.
29. Chang KP, Yu JS, Chien KY, Lee CW, Liang Y, Liao CT, Yen TC, Lee LY, Huang LL, Liu SC, Chang YS, Chi LM. Identification of PRDX4 and P4HA2 as metastasis-associated proteins in oral cavity squamous cell carcinoma by comparative tissue proteomics of microdissected specimens using iTRAQ technology. J Proteome Res 2011, 10:4935-4947. 10.1021/pr200311p, 21859152.
30. Haura EB, Muller A, Breitwieser FP, Li J, Grebien F, Colinge J, Bennett KL. Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res 2011, 10:182-190. 10.1021/pr100863f, 3017669,3017669, 20945942.
31. Hou Q, Tan HT, Lim KH, Lim TK, Khoo A, Tan IB, Yeoh KG, Chung MC. Identification and functional validation of caldesmon as a potential gastric cancer metastasis-associated protein. J Proteome Res 2013, 12:980-990. 10.1021/pr3010259, 23265641.
32. Masui O, White NM, DeSouza LV, Krakovska O, Matta A, Metias S, Khalil B, Romaschin AD, Honey RJ, Stewart R, Pace K, Bjarnason GA, Siu KW, Yousef GM. Quantitative proteomic analysis in metastatic renal cell carcinoma reveals a unique set of proteins with potential prognostic significance. Mol Cell Prot 2013, 12:132-144.
33. Qin X, Chen Q, Sun C, Wang C, Peng Q, Xie L, Liu Y, Li S. High-throughput screening of tumor metastatic-related differential glycoprotein in hepatocellular carcinoma by iTRAQ combines lectin-related techniques. Med Oncol 2013, 30:420.
34. Ross PL, Huang YN, Marchese JN, Williamson B, Parker K, Hattan S, Khainovski N, Pillai S, Dey S, Daniels S, Purkayastha S, Juhasz P, Martin S, Bartlet-Jones M, He F, Jacobson A, Pappin DJ. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Prot 2004, 3:1154-1169.
35. He X, Wang Y, Zhang W, Li H, Luo R, Zhou Y, Li C, Liao M, Huang H, Lv X, Xie Z, He M. Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS/MS. Neoplasma 2014, 61:10.
36. Ko CH, Cheng CF, Lai CP, Tzu TH, Chiu CW, Lin MW, Wu SY, Sun CY, Tseng HW, Wang CC, Kuo ZK, Wang LM, Chen SF. Differential proteomic analysis of cancer stem cell properties in hepatocellular carcinomas by isobaric tag labeling and mass spectrometry. J Proteome Res 2013, 12:3573-3585. 10.1021/pr4004294, 23782096.
37. Huang C, Wang Y, Liu S, Ding G, Liu W, Zhou J, Kuang M, Ji Y, Kondo T, Fan J. Quantitative proteomic analysis identified paraoxonase 1 as a novel serum biomarker for microvascular invasion in hepatocellular carcinoma. J Proteome Res 2013, 12:9.
38. Wang C, Guo K, Gao D, Kang X, Jiang K, Li Y, Sun L, Zhang S, Sun C, Liu X, Wu W, Yang P, Liu Y. Identification of transaldolase as a novel serum biomarker for hepatocellular carcinoma metastasis using xenografted mouse model and clinic samples. Cancer Lett 2011, 313:154-166. 10.1016/j.canlet.2011.08.031, 22023829.
39. Yu Y, Pan X, Ding Y, Liu X, Tang H, Shen C, Shen H, Yang P. An iTRAQ based quantitative proteomic strategy to explore novel secreted proteins in metastatic hepatocellular carcinoma cell lines. Analyst 2013, 138:4505-4511. 10.1039/c3an00517h, 23752568.
40. Feng H, Li X, Niu D, Chen WN. Protein profile in HBx transfected cells: a comparative iTRAQ-coupled 2D LC-MS/MS analysis. J Proteomics 2010, 73:1421-1432. 10.1016/j.jprot.2009.12.004, 20026004.
41. Feng H, Wang M, Chen WN. iTRAQ-coupled 2D LC-MS/MS analysis of secreted proteome of HBV-replicating HepG2 cells: potential in biomarkers for prognosis of HCC. Curr Microbiol 2010, 61:280-284. 10.1007/s00284-010-9608-3, 20165850.
42. Bee A, Ke Y, Forootan S, Lin K, Beesley C, Forrest SE, Foster CS. Ribosomal protein l19 is a prognostic marker for human prostate cancer. Clin Cancer Res 2006, 12:2061-2065. 10.1158/1078-0432.CCR-05-2445, 16609016.
43. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23:3189-3199. 10.1038/sj.onc.1207545, 15094768.
44. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 2001, 33:637-668. 10.1016/S1357-2725(01)00046-2, 11390274.
45. Nagy N, Bronckart Y, Camby I, Legendre H, Lahm H, Kaltner H, Hadari Y, Van Ham P, Yeaton P, Pector JC, Zick Y, Salmon I, Danguy A, Kiss R, Gabius HJ. Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor. Gut 2002, 50:392-401. 10.1136/gut.50.3.392, 1773143, 11839721.
46. Okamoto H, Yasui K, Zhao C, Arii S, Inazawa J. PTK2 and EIF3S3 genes may be amplification targets at 8q23-q24 and are associated with large hepatocellular carcinomas. Hepatology 2003, 38:1242-1249. 10.1053/jhep.2003.50457, 14578863.
47. Pogue-Geile K, Geiser JR, Shu M, Miller C, Wool IG, Meisler AI, Pipas JM. Ribosomal protein genes are overexpressed in colorectal cancer: isolation of a cDNA clone encoding the human S3 ribosomal protein. Mol Cell Biol 1991, 11:3842-3849. 361167, 1712897.
48. Rabinovich GA, Ilarregui JM. Conveying glycan information into T-cell homeostatic programs: a challenging role for galectin-1 in inflammatory and tumor microenvironments. Immunol Rev 2009, 230:144-159. 10.1111/j.1600-065X.2009.00787.x, 19594634.
49. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol 2002, 34:1430-1448. 10.1016/S1357-2725(02)00041-9, 12200037.
50. Yang Z, Tao T, Raftery MJ, Youssef P, Di Girolamo N, Geczy CL. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol 2001, 69:986-994.
51. Schmitz W, Albers C, Fingerhut R, Conzelmann E. Purification and characterization of an alpha-methylacyl-CoA racemase from human liver. Eur J Biochem 1995, 231:815-822. 10.1111/j.1432-1033.1995.tb20766.x, 7649182.
52. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002, 62:2220-2226.
53. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371. 10.1038/nrc2628, 19343034.
54. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40. 10.1038/35065000, 11242034.
55. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer 2010, 102:639-644. 10.1038/sj.bjc.6605530, 2837572, 20087353.
56. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466. 10.1038/nature02924, 15329734.
57. Huang X, Wei W, Ya N, Zeng J, Zeng Y, Ma C, Chi M, Wu Y, Li Y, Huang Y, Zhang X, Huang A, Liu J. A mathematical model to predict short-term recurrence and metastasis of primary hepatocellular carcinoma larger than 10 cm in diameter. Hepatogastroenterology 2013, 60:225-230.
58. Wang ZS, Wu LQ, Yi X, Geng C, Li YJ, Yao RY, Hu WY, Han B. CK19 can be used to predict the early recurrence and prognosis of HBV-related hepatocellular carcinoma patients with low AFP serum concentration after R0 radical hepatectomy. Zhonghua Zhong Liu Za Zhi 2012, 34:753-758.
59. Lv Y, Wang W, Jia WD, Sun QK, Li JS, Ma JL, Liu WB, Zhou HC, Ge YS, Yu JH, Xia HH, Xu GL. High-level expression of periostin is closely related to metastatic potential and poor prognosis of hepatocellular carcinoma. Med Oncol 2013, 30:385.
60. Lau SH, Sham JS, Xie D, Tzang CH, Tang D, Ma N, Hu L, Wang Y, Wen JM, Xiao G, Zhang WM, Lau GK, Yang M, Guan XY. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006, 25:1242-1250. 10.1038/sj.onc.1209141, 16247463.
61. Garcia AF, Garcia W, Nonato MC, Araujo AP. Structural stability and reversible unfolding of recombinant porcine S100A12. Biophys Chem 2008, 134:246-253. 10.1016/j.bpc.2008.02.013, 18346834.
62. Thierolf M, Hagmann ML, Pfeffer M, Berntenis N, Wild N, Roessler M, Palme S, Karl J, Bodenmuller H, Ruschoff J, Rossol S, Rohr G, Rosch W, Friess H, Eickhoff A, Jauch KW, Langen H, Zolg W, Tacke M. Towards a comprehensive proteome of normal and malignant human colon tissue by 2-D-LC-ESI-MS and 2-DE proteomics and identification of S100A12 as potential cancer biomarker. Proteomics Clin Appl 2008, 2:11-22. 10.1002/prca.200780046, 21136775.
63. Jiang Z, Fanger GR, Woda BA, Banner BF, Algate P, Dresser K, Xu J, Chu PG. Expression of alpha-methylacyl-CoA racemase (P504s) in various malignant neoplasms and normal tissues: astudy of 761 cases. Hum Pathol 2003, 34:792-796. 10.1016/S0046-8177(03)00268-5, 14506641.
64. Helal Tel A, Radwan NA, Abdel Kader Z, Helmy NA, Hammad SY. Role of alpha methylacyl-coenzyme A racemase in differentiating hepatocellular carcinoma from dysplastic and nondysplastic liver cell lesions. Ann Diagn Pathol 2012, 16:330-334. 10.1016/j.anndiagpath.2012.01.003, 22542076.
65. Mozos A, Sole M, Miquel R, Petit A, Nadal A, Fernandez PL. Usefulness and limitations of alpha-methylacyl-CoA racemase expression in the hepatobiliary system and pancreas: a wide tissue microarray analysis of normal and neoplastic epithelia. Anal Quant Cytol Histol 2010, 32:261-268.
66. Dabritz J, Langhorst J, Lugering A, Heidemann J, Mohr M, Wittkowski H, Krummenerl T, Foell D. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12. Inflamm Bowel Dis 2013, 19:1130-1138. 10.1097/MIB.0b013e318280b1cd, 23377171.
67. Barry M, Dhillon PK, Stampfer MJ, Perner S, Ma J, Giovannucci E, Kurth T, Mucci LA, Rubin MA. alpha-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study. Prostate 2012, 72:301-306. 10.1002/pros.21432, 3267640, 21713964.
68. Iizuka N, Oka M, Yamada-Okabe H, Nishida M, Maeda Y, Mori N, Takao T, Tamesa T, Tangoku A, Tabuchi H, Hamada K, Nakayama H, Ishitsuka H, Miyamoto T, Hirabayashi A, Uchinmura S, Hamamoto Y. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003, 361:923-929. 10.1016/S0140-6736(03)12775-4, 12648972.
69. Garbis SD, Tyritzis SI, Roumeliotis T, Zerefos P, Giannopoulou EG, Vlahou A, Kossida S, Diaz J, Vourekas S, Tamvakopoulos C, Pavlakis K, Sanoudou D, Constantinides CA. Search for potential markers for prostate cancer diagnosis, prognosis and treatment in clinical tissue specimens using amine-specific isobaric tagging (iTRAQ) with two-dimensional liquid chromatography and tandem mass spectrometry. J Proteome Res 2008, 7:3146-3158. 10.1021/pr800060r, 18553995.